Michael Dunne, M.D., is Chief Medical Officer and Head of Development at Bill & Melinda Gates Medical Research Institute. He has held various senior level C-suite roles in connection with the clinical development of numerous infectious disease compounds including Chief Scientific Officer of Iterum Therapeutics where he now serves a Strategic Advisor on the Board of Directors. Dr. Dunne served as Chief Medical Officer of Durata Therapeutics which was acquired by Actavis in 2014. He worked at Pfizer in numerous roles of increasing responsibility including Vice President, Therapeutic Head of Development for Infectious Disease from 2001 to 2009. Dr. Dunne received a B.A. in Economics from Northwestern University and M.D. from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.